$RLYP (Relypsa, Inc.)

$RLYP {{ '2016-07-26T10:34:24+0000' | timeago}} • Announcement

WeissLaw said it is investigating whether $RLYP's Board acted in the best interests of its shareholders to maximize shareholder value prior to entering into agreement. At least one analyst had set a target price of $51 per share.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$VRX {{ '2017-07-17T14:04:54+0000' | timeago}} • Announcement

$VRX has entered into an agreement to sell its Obagi Medical Products business for $190MM in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. The transaction is expected to close in second half of 2017. $VRX intends to use the proceeds from the sale to permanently repay term loan debt under its Senior Secured Credit Facility.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$VRX {{ '2017-07-10T13:27:06+0000' | timeago}} • Announcement

$VRX pays down $811MM of senior secured term loans using the net proceeds of the sale of Dendreon Pharmaceuticals LLC. The company has now reduced its debt by more than $4.3Bil since the end of 1Q16. $VRX still expects to pay down $5Bil in debt from divestiture proceeds and free cash flow within 18 months of August 2016.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$ZTS {{ '2017-06-16T17:01:44+0000' | timeago}} • Announcement

Nexvet Biopharma, $ZTS, and Zoetis Belgium jointly dispatched a letter to the holders of convertible securities of Nexvet in accordance with Rule 15 of the Irish Takeover Rules to provide information regarding how the Acquisition of Nexvet by $ZTS will affect such securities.

$AMGN {{ '2017-06-07T14:18:46+0000' | timeago}} • Announcement

$AMGN and $AGN said that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the Biologics License Application (BLA) for ABP 215, a biosimilar candidate to Avastin (bevacizumab), on July 13, 2017. Bevacizumab is medication used to treat types of cancers and specific eye disease.

$AGN {{ '2017-06-07T14:08:57+0000' | timeago}} • Announcement

$AGN's subsidiary Allergan Sales LLC agreed to buy privately-held Keller Medical, a medical device company and developer of the Keller Funnel. The Keller Funnel is a cone-shaped, lubricated plastic funnel that reduces surgeon and patient contact during breast augmentation or reconstruction procedures.

$MCK {{ '2017-05-24T20:45:05+0000' | timeago}} • Announcement

The Board of Directors of $MCK declared a regular dividend of $0.28 per share on common stock. The dividend will be payable on July 3, 2017, to stockholders of record on June 5, 2017.

$AGN {{ '2017-05-24T14:41:46+0000' | timeago}} • Announcement

$AGN announced the early tender results for tender offers commenced by its subsidiaries Allergan Funding SCS, Allergan Finance LLC, Forest Laboratories, and Allergan Inc., each as co-offeror with $AGN's subsidiary Warner Chilcott Ltd., to purchase for cash certain debt securities issued by the entities.

$AGN {{ '2017-05-23T12:27:35+0000' | timeago}} • Announcement

$AGN began an offering of senior unsecured notes in multiple tranches in a registered public offering. The notes will be issued by its indirect subsidiary Allergan Funding SCS and guaranteed by its indirect subsidiaries Warner Chilcott, Allergan Capital and Allergan Finance.

$MCK {{ '2017-05-18T22:30:24+0000' | timeago}} • Webcast

$MCK stated that on the buy side for generics, the company is seeing a deflation going forward. However, the company added that deflation is not a big factor that plays into the way its economics or P&L operates.

$MCK {{ '2017-05-18T21:05:10+0000' | timeago}} • Announcement

During 4Q17, $MCK's Distribution Solution revenues rose 5% YoY to $48.2Bil. Revenues of North America pharmaceutical distribution and services revenues were $40.6Bil, up 5%. International pharmaceutical distribution and services revenues were $6.1Bil and Medical-Surgical distribution and services revenues were $1.6Bil.

$MCK {{ '2017-05-18T21:01:30+0000' | timeago}} • Announcement

$MCK reported an increase in 4Q17 profit, due to a pre-tax gain of $3.9Bil related to the previously announced creation of the Change Healthcare joint venture. Net income rose to $3.6Bil, or $16.95 per share, compared to $431MM, or $1.97 per share during 4Q16. Revenues rose 4% YoY to $46.7Bil during the quarter.

$ZTS {{ '2017-05-11T20:52:27+0000' | timeago}} • Announcement

$ZTS BoD declared 3Q17 dividend of $0.105 per share, payable to holders of the company’s common stock. The dividend is payable on Sept. 1, 2017, to holders of record on June 15, 2017.

$ZTS {{ '2017-05-11T11:47:10+0000' | timeago}} • Announcement

$ZTS announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich. $ZTS will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. $ZTS expects to add up to 45 manufacturing positions in the next 3 years.

$AGN {{ '2017-05-09T19:02:30+0000' | timeago}} • Webcast

On M&A, $AGN commented that the company is in a strong position currently with no need to do large M&A, with the caveat that it will always be opportunistic. Additionally, $AGN said that the company's focus is on steppingstones and continuing to advance its own strategy.

$AGN {{ '2017-05-09T18:53:46+0000' | timeago}} • Webcast

$AGN's outlook for 2Q17 is higher and expects revenue in the range of $3.9-4Bil. GM for 2Q17 will be lower than 1Q17, largely due to product mix; full quarter for LifeCell, two quarters of ZELTIQ in 2Q17, which has lower GMs. Additionally, Minastrin is having its first full quarter going generic.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, February 28 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, February 28 2017 - 1:00pm
ZTS (Zoetis Inc.)
Thursday, February 16 2017 - 1:30pm
ONVO (Organovo Holdings, Inc.)
Thursday, February 9 2017 - 10:00pm
PTN (Palatin Technologies Inc.)
Thursday, February 9 2017 - 4:00pm
MCK (McKesson Corporation)
Wednesday, January 25 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 8 2016 - 1:00pm
ZTS (Zoetis Inc.)
Wednesday, November 2 2016 - 12:30pm
MCK (McKesson Corporation)
Thursday, October 27 2016 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, September 20 2016 - 3:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 9 2016 - 12:00pm

AlphaGraphics you may like